Wntrix Overview

  • Founded
  • 2014

  • Status
  • Private

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $225K

  • Investors
  • 2

Wntrix General Information


Developer of antibody drugs created for the treatment of cancer. The company's antibody-drug conjugate pipeline combines the capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, enabling the medical community to improve treatment outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Primary Office
  • 2450 Holcombe Boulevard
  • Suite J
  • Houston, TX 77021
  • United States
+1 (346) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Wntrix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 01-May-2017 $225K Completed Pre-Clinical Trials
1. Accelerator/Incubator 02-Mar-2016 Completed Pre-Clinical Trials
To view Wntrix’s complete valuation and funding history, request access »

Wntrix Executive Team (2)

Name Title Board Seat Contact Info
Jie Cui Interim Chief Executive Officer & Director
Qingyun Liu President & Director
To view Wntrix’s complete executive team members history, request access »

Wntrix Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
U.S. Department of Health and Human Services Government 000 0000 000000 0
Johnson & Johnson Innovation - JLABS Accelerator/Incubator 000 0000 000000 0
To view Wntrix’s complete investors history, request access »